Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer ; volume:15 ; number:1 ; day:8 ; month:4 ; year:2015 ; pages:1-15 ; date:12.2015
BMC cancer ; 15, Heft 1 (8.4.2015), 1-15, 12.2015
- Creator
-
Larsen, Sarah L.
- Contributor
-
Yde, Christina W.
Laenkholm, Anne-Vibeke
Rasmussen, Birgitte B.
Duun-Henriksen, Anne Katrine
Bak, Martin
Lykkesfeldt, Anne E.
Kirkegaard, Tove
SpringerLink (Online service)
- DOI
-
10.1186/s12885-015-1210-4
- URN
-
urn:nbn:de:1111-2016110621190
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:00 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Larsen, Sarah L.
- Yde, Christina W.
- Laenkholm, Anne-Vibeke
- Rasmussen, Birgitte B.
- Duun-Henriksen, Anne Katrine
- Bak, Martin
- Lykkesfeldt, Anne E.
- Kirkegaard, Tove
- SpringerLink (Online service)
Other Objects (12)
Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells
TROP2 methylation and expression in tamoxifen-resistant breast cancer
Heregulin β1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells
Targeting cholesterol-rich microdomains to circumvent tamoxifen-resistant breast cancer
Long non-coding RNA SOX2OT in tamoxifen-resistant breast cancer
Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1
Correction to: Heregulin β1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells
Aurora kinases as targets in drug-resistant neuroblastoma cells
Downregulation of miR-342 is associated with tamoxifen resistant breast tumors
Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression
Advanced materials for corrosion resistant coatings
Protease‐resistant streptavidin for interaction proteomics
Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells
TROP2 methylation and expression in tamoxifen-resistant breast cancer
Heregulin β1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells
Targeting cholesterol-rich microdomains to circumvent tamoxifen-resistant breast cancer
Long non-coding RNA SOX2OT in tamoxifen-resistant breast cancer
Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1
Correction to: Heregulin β1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells
Aurora kinases as targets in drug-resistant neuroblastoma cells
Downregulation of miR-342 is associated with tamoxifen resistant breast tumors
Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression
Advanced materials for corrosion resistant coatings
Protease‐resistant streptavidin for interaction proteomics
Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells
TROP2 methylation and expression in tamoxifen-resistant breast cancer
Heregulin β1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells
Targeting cholesterol-rich microdomains to circumvent tamoxifen-resistant breast cancer
Long non-coding RNA SOX2OT in tamoxifen-resistant breast cancer
Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1
Correction to: Heregulin β1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells
Aurora kinases as targets in drug-resistant neuroblastoma cells
Downregulation of miR-342 is associated with tamoxifen resistant breast tumors
Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression
Advanced materials for corrosion resistant coatings